1. Introduction {#s0005}
===============

Viral pandemics remain serious threats to humankind. Every year, known viruses such as HIV-1 and hepatitis B virus newly infect millions of people across the globe. In addition, recent outbreaks of Ebola virus, influenza virus, severe acute respiratory syndrome (SARS) coronavirus and Middle East respiratory syndrome-coronavirus (MERS-CoV) serve as a reminder of the silent danger. The World Health Organization reported in 2015 that over 1.34 million causalities per year are connected with hepatitis B and almost 500,000 with hepatitis C. Occasional epidemic outbreaks of other viruses are also striking. These include outbreaks of noroviruses, flaviviruses (Zika and dengue viruses), new strains of influenza viruses, the re-emergence of West Nile virus in Italy and the United States. Despite relatively long pauses, viruses such as influenza virus can re-emerge and cause global pandemic health problems.

Unlike cellular genomes, which consist of double-stranded (ds) DNA, viral genomes can be formed by a broad variety of nucleic acids (NAs), including ds or single-stranded (ss) circular or linear DNA or positive-, negative- or sometimes ambi-sense RNA. As viral life cycles are dependent on cellular factors and cellular metabolic and signaling pathways, the number of possible antiviral drug targets is limited. However, almost all viruses encode unique proteins and enzymes that may serve as specific targets for antiviral therapy. The overarching goal of modern drug development efforts is to design compounds that specifically inhibit viral targets or cellular targets essential for virus replication.

The purpose of this review is to provide insight into the broad variety of cell-based and biochemical assays used for identification and evaluation of antivirotics, including high-throughput screening (HTS) methods. An overview of available inhibitors and vaccines, which has been reviewed elsewhere \[e.g. in ([@bb0400])\], is beyond the scope of this paper.

1.1. Morphology {#s0010}
---------------

To package their genomes into particles of very limited size, viruses encode few genes. Virions consist of an RNA or DNA genome that is protected by an outer shell called a capsid (also nucleocapsid) formed by a lattice of capsid proteins. In enveloped viruses, the capsid is additionally surrounded by a lipid bilayer spiked with viral proteins. The size of animal viruses ranges from approximately 25 nm to over 300 nm ([@bb0340]). The capsids and virions of RNA viruses adopt various shapes. Viral capsids may be icosahedral (e.g. *Picornaviridae*, *Astroviridae*, *Reoviridae*, *Togaviridae*), bullet-shaped (*Rhabdoviridae*), helical (*Coronaviridae*), helical filamentous (*Filoviridae*, *Orthomyxoviridae*, *Paramyxoviridae*), or filamentous (*Arenaviridae*, *Bunyaviridae*). The retroviral capsid core may be conical, spherical, or rod-shaped.

The morphology of DNA viruses is similarly diverse, ranging from icosahedral (enveloped - *Hepadnaviridae*, *Herpesvridae*; nonenveloped - *Adenoviridae*, *Parvovirdae*, *Polyomaviridae* and *Papillomaviridae*) to rod-shaped (*Baculoviridae*) or pleomorphic (*Poxviridae*).

1.2. Structure {#s0015}
--------------

The viral life cycle is the process of viral replication in a host cell. First, viruses enter the host cell and replicate their genomes. Following translation of viral proteins by the host cell machinery, viruses package their genomic material into protective proteinaceous capsids and exit the cell to infect another host cell. Nonenveloped viruses consist only of a protein capsid shell enclosing the viral genome and enzymes, while the capsid shell of enveloped viruses is enclosed in a lipid envelope derived from the host cell membrane. Regardless of whether the virus is enveloped, its surface must display (glyco)proteins suitable for specific interactions with host cell receptors. In contrast to the surface proteins of nonenveloped viruses, those of enveloped viruses usually serve another function in addition to host cell recognition and attachment. For example, they may enable fusion of the viral and cellular membranes, usually through an interaction with a secondary receptor(s) or co-receptor(s). The fusion domains of viral surface glycoproteins thus can lower the kinetic barrier for the energetically demanding membrane fusion.

The viral particle must be sufficiently stable to protect the genome until its delivery into the host cell. Simultaneously, it must be metastable, to allow its disassembly and release of the genome for replication in the infected cell at the appropriate time. The energetic barrier that prevents viral disassembly outside the cell is lowered upon infection by structural changes in the viral components. These changes may be induced by binding of a cellular ligand or by changes in the environment, such as pH change upon entering a specific cellular compartment. Numerous viruses preassemble immature particles that undergo irreversible (usually proteolytic) transitions into mature structures of fully infectious virions. Mutual interactions of viral capsid proteins are typically different from those of cellular proteins, which predominantly create binary interactions. Viral structural proteins interact with multiple neighboring partners to form multicomponent macromolecular structures \[reviewed in ([@bb0290], [@bb0835])\]. The economy of the packaged viral genomes due to the limited capsid size implies formation of only a few types of structural proteins, which are usually symmetrically organized \[reviewed in ([@bb1410], [@bb1430])\].

2. Common stages in the viral life cycle {#s0020}
========================================

In the initial stage of infection, viruses must overcome several obstacles. The first is the cellular plasma membrane with an actin cortex. Then, they must traffic through dense cytoplasm to reach their final destination for replication and assembly. These pathways are specific for different viruses and often are dictated by the size of the particle and its structure.

The viral life cycle can be divided into several common stages, including entry, uncoating, genome replication, genome packaging and assembly, release, and maturation ([Fig. 1](#f0005){ref-type="fig"} ).Fig. 1Simplified scheme of common stages of viral life cycle targeted by antiviral drugs. These stages including: 1) attachment and entry, 2) uncoating, 3) genome replication, 4) genome packaging and assembly of viral particle and 5) virus release and maturation.Fig. 1

2.1. Entry into the cell {#s0025}
------------------------

In general, the first phase of viral infection is specific recognition of the target host cell and binding to a surface receptor displayed on the cell membrane. This process is common to both enveloped and nonenveloped viruses. In enveloped viruses, the binding is mediated by viral surface components, typically oligomers of integral glycoproteins. Nonenveloped viruses bind receptors through sites or projections on the capsid surface. Viruses can use either a single receptor (e.g. TIM-1 for hepatitis A virus, GM1 for SV40, CD155 for poliovirus, low-density lipoprotein receptor for human rhinovirus) or multiple receptors with equivalent roles (e.g., Nectin-1/2 or HVEM for herpes simplex virus 1/2, ACE or L-SIGN for SARS coronavirus). For other viruses (e.g. HIV, HCV, adenoviruses, rotaviruses, picornaviruses, and some herpesviruses), the presence of at least two cytoplasmic membrane components is required. For example, HIV-1 binds to the primary receptor CD4 and one of two co-receptors (CCR5 or CXCR4) \[reviewed in ([@bb0365], [@bb0640])\].

To infect a cell, viruses must overcome the plasma membrane to deliver their genetic material into the cytosol. Viruses enter cells by two main mechanisms. A majority of animal viruses, both enveloped and nonenveloped, enter cells by one or two types of endocytosis, such as clathrin-mediated endocytosis (e.g. VSV, influenza A virus, rhinovirus), caveolin-mediated uptake (echovirus, polyoma virus), clathrin/caveolin-independent endocytosis such as caveolar or lipid raft-mediated (e.g. SV40, polyomavirus mouse), or macropinocytosis (e.g. vaccinia virus, respiratory syncytial virus, Ebola virus, HIV-1) ([@bb0145], [@bb0365], [@bb0515], [@bb0915], [@bb1160], [@bb1170], [@bb1200], [@bb1345], [@bb1455], [@bb1515]). These endocytic mechanisms enable the virus to be transported by the cell's machinery through the plasma membrane and to pass through the dense actin cortex. Cellular entry of some viruses is coupled with receptor-mediated signaling, resulting in activation of molecules that facilitate virus entry by cytoskeleton reorganization, induction of long-distance transport of the virus-containing vesicles, or actin cortex disassembly. The second type of entry is used by some enveloped viruses (paramyxo-, herpes-, and retroviruses), which upon cell surface receptor binding, infect the cell by direct fusion of viral and plasma membranes at neutral pH.

Upon internalization, most viruses become trapped and enclosed in vesicles that pinch off the inner side of the plasma membrane and transport their cargo into the cytoplasm. On their way through the cell, these transport vesicles undergo maturation by fusing with other vesicles. To fulfill their task of genome replication, viruses have to escape from these endosomes. The "great escape" is triggered by activation of a fusion or penetration mechanism, such as changes in conditions in the endosomal interior \[e.g. pH, ionic environment (e.g. calcium ion concentration), oxido-reducing conditions\], changes in membrane composition, and other physico-chemical cues ([@bb0145], [@bb0365], [@bb0795]). Depending on the requirements for a particular virus, these events can occur in early endosomes (pH 6.5--6.0; e.g. hepatitis C virus, vesicular stomatitis virus), late endosomes (pH 6.0--5.0; e.g. influenza A virus, dengue virus, SARS coronavirus), recycling endosomes, macropinosomes, the endoplasmic reticulum, the Golgi apparatus, or lysosomes (pH 5.0--4.5) ([@bb0145], [@bb0365], [@bb0640], [@bb0795]). For the majority of animal viruses, the activation of these fusion or penetration mechanisms occurs through conformational changes and structural rearrangements in viral surface proteins and/or the whole virion shell that may destabilize the capsid core. Structural rearrangements in enveloped viruses usually mediate fusion of viral and endosomal membranes. In nonenveloped viruses, the structural changes uncover amphipathic or hydrophobic domains that may induce pore formation or disruption of endosomal membranes. To deliver genetic material to the replication site, these mechanisms ultimately release viral capsid structures from endosomal vesicles into the cytosol either by fusing with the endosomal membrane (enveloped viruses) or by penetrating the endosomal membrane (nonenveloped viruses).

2.2. Uncoating {#s0030}
--------------

Uncoating is the partial or complete disassembly of the protective capsid shell and/or lipid envelope to liberate the viral genome. For many viruses, this process is closely connected with conformational changes induced by the virus binding to the cell surface receptor; a low pH environment; or changes in oxido-reducing conditions, ion concentrations, or other factors. For enveloped viruses, uncoating involves a loss of the viral membrane by fusion either with the plasma membrane or with intracellular vesicles, followed by stepwise uncoating of the protective capsid shell. In nonenveloped viruses, the uncoating process typically involves conformational changes that result in the weakening of intermolecular interactions, loss of structural proteins, proteolytic cleavage, and so on ([@bb0515]).

Depending on the virus, uncoating can take place at the plasma membrane, in the cytoplasm, during endocytosis in early or late endosomes, in lysosomes, in the nucleus, or at the nuclear pore complex (NPC).

The ssRNA genome of retroviruses, which is fully enclosed inside a protective capsid shell, must be reverse transcribed into dsDNA and released from the capsid. Although it is accepted that HIV-1 uncoating is linked to reverse transcription and nuclear import ([@bb0040]) and is controlled by host factors (e.g. cyclophilin A, TRIM5α), the precise molecular mechanisms that trigger the uncoating remain unknown. Several hypotheses have been proposed, including breakage of the capsid shell due to increased inner pressure caused by accumulation of the reverse transcription product ([@bb1450]), the requirement of intact microtubules and dynein and kinesin motors ([@bb1110]), and phosphorylation of capsid shell protein by the host cell kinase MELK ([@bb1650]).

2.3. Entry into the nucleus {#s0035}
---------------------------

In contrast to the majority of RNA viruses, which replicate in the cytoplasm, most DNA viruses (with the exception of large DNA viruses including *Poxviridae*, *Asfarviridae*, and *Mimiviridae*) and several negative stranded RNA viruses enter the nucleus to replicate their genomes ([@bb0925], [@bb0940]). Passive diffusion into the nucleus is suitable for molecules smaller than 9 nm in diameter, but larger structures must enter through the nuclear pore complex (NPC), which can accommodate molecules of up to 39 nm ([@bb1330]). Translocation through the NPC is tightly regulated and requires the presence of a nuclear localization signal (NLS) on the passing molecule and nuclear import receptors (importins or karyopherins) ([@bb0255]).

Due to the diversity of viral particle sizes (from 25 nm to over 300 nm) and structures, viruses have evolved several strategies to export their DNA or RNA genome into the nucleoplasm. With regard to the NPC, these pathways can be divided into NPC-dependent and NPC-independent mechanisms. Due to size limitations, only a few, very small viral capsid particles, such as hepatitis B virus (HBV; 32--36 nm diameter), can pass through the NPC ([@bb0340], [@bb1425]) in an importin-dependent manner. HBV then disassembles at the nuclear side of the NPC (the nuclear basket), releasing its genome into the nucleoplasm ([@bb0485]). The capsid shells or ribonucleoprotein complexes (RNPs) of some larger viruses, such as influenza A virus and HIV-1, disassemble within the cytoplasm. The viral genome, released from the shell and complexed with NLS-containing components, is then translocated through the NPC ([@bb0040], [@bb0210], [@bb0340], [@bb0485], [@bb0785]). Another mechanism, used by herpes simplex virus (HSV) and adenoviruses, involves cellular (importins, Nup) or viral protein-mediated attachment (docking) of the capsid shell at the cytoplasmic side of the NPC. This facilitates the passage of genomic DNA into the NPC either by ejection from an almost intact particle (through the capsid portal in HSV-1) or upon complete disassembly of the capsid shell (in adenoviruses) ([@bb0945], [@bb1295], [@bb1350]). NPC-independent mechanisms are used by some retroviruses (e.g. MLV) that enter the nucleus during the mitotic phase of the cell division cycle when the nuclear envelope is dissolved ([@bb1165], [@bb1485]). Another mechanism, described for parvoviruses, involves partial disruption of the nuclear envelope ([@bb0335], [@bb0485]).

2.4. Replication {#s0040}
----------------

Viral genomes can be encoded by various types of NAs, as summarized in [Table 1](#t0005){ref-type="table"} for DNA viruses and [Table 2](#t0010){ref-type="table"} for RNA viruses. By convention, ssDNA of equivalent polarity to mRNA is designated as the positive (+) strand. The complementary ssNAs are of minus polarity (−). The majority of DNA viruses replicate in the nucleus, where cellular DNA replication and transcription also occur. In contrast, RNA viruses usually replicate in the cytoplasm.Table 1Basic characteristics of DNA viruses.Table 1DNA virusesGenomReplicationVirus familyDNA type/topologyPolarityEnzymeIntracellular siteAdenoviridaeds/linearBothViral DNA polymeraseNucleusAnelloviridaess/circular(−)Cellular DNA polymeraseNucleusAsfarviridaeds/linearBothViral DNA polymeraseCytoplasmCircoviridaess/circular(−) or ambisenseCellular DNA polymeraseNucleusHepadnaviridaeds/linearBothViral reverse transcriptaseNucleus/cytoplasmHerpesviridaeds/linearBothViral DNA polymeraseNucleusIridoviridaeds/linearBothViral DNA polymeraseNucleus/cytoplasmPapillomaviridaeds/circularBothCellular DNA polymeraseNucleusParvoviridaess/linearEitherCellular DNA polymeraseNucleusPolyomaviridaeds/circularBothCellular DNA polymeraseNucleusPoxviridaeds/linearBothViral DNA polymeraseCytoplasmTable 2Basic characteristics of RNA viruses.Table 2RNA virusesGenomReplicationVirus familyRNA type/segment/topologyPolarityEnzymeIntracellular siteArenaviridaessRNA/2/linearAmbisenseVirion RNA polymeraseCytoplasmArteriviridaessRNA/1/linear(+)Viral RNA polymeraseCytoplasmAstroviridaessRNA/1/linear(+)Viral RNA polymeraseCytoplasmBirnaviridaedsRNA/2/linearbothVirion RNA polymeraseCytoplasmBornaviridaessRNA/1/linear(−)Virion RNA polymeraseNucleusBunyaviridaessRNA/3/linear(−) or ambisenseVirion RNA polymeraseCytoplasmCaliciviridaessRNA/1/linear(+)Viral RNA polymeraseCytoplasmCoronaviridaessRNA/1/linear(+)Viral RNA polymeraseCytoplasmDeltavirusssRNA/1/circular(−)RNA polymerase IINucleusFiloviridaessRNA/1/linear(−)Virion RNA polymeraseCytoplasmFlaviviridaessRNA/1/linear(+)Viral RNA polymeraseCytoplasmHepeviridaessRNA/1/linear(+)Viral RNA polymeraseCytoplasmNodaviridaessRNA/2/linear(+)Viral RNA polymeraseCytoplasmOrthomyxoviridaessRNA/6-8/linear(−)Virion RNA polymeraseNucleusParamyxoviridaessRNA/1/linear(−)Virion RNA polymeraseCytoplasmPicornaviridaessRNA/1/linear(+)Viral RNA polymeraseCytoplasmReoviridaedsRNA/10-12/linearbothVirion RNA polymeraseCytoplasmRetroviridaessRNA/2/linear(+)Virion reverse transcriptaseNucleus/cytoplasmRhabdoviridaessRNA/1/linear(−)Virion RNA polymeraseCytoplasmTogaviridaessRNA/1/linear(+)Viral RNA polymeraseCytoplasm

### 2.4.1. Replication of RNA viruses {#s0045}

RNA viruses are the only "organisms" that store their genetic information in the form of RNA. Replication of their genomes is accomplished either by RNA-dependent RNA synthesis ([Fig. 2](#f0010){ref-type="fig"}A, B) \[reviewed in ([@bb0510], [@bb1095], [@bb1195], [@bb1375], [@bb1670])\] or through RNA-dependent DNA synthesis (reverse transcription) followed by DNA integration, replication, and transcription ([Fig. 2](#f0010){ref-type="fig"}C). As some of these enzymatic activities are not commonly found in uninfected host cells, RNA viruses must encode enzymes to aid replication ([Table 2](#t0010){ref-type="table"}). RNA viruses are divided according to the Baltimore classification into dsRNA viruses (*Birna-* and *Reoviridae*); positive-sense ssRNA viruses (*Corona-, Flavi-,* and *Picornaviriade*); negative-sense ssRNA viruses (*Filo-*, *Rhabdo-*, *Paramyxo-*, and *Orthomyxoviriade*), and ambisense RNA viruses (*Arena-* and some members of *Bunyaviridae*) with both positive- and negative-sense RNAs ([@bb1280]) (see [Table 2](#t0010){ref-type="table"}).Fig. 2Simplified scheme of replication of ss (+)RNA viruses (A), dsRNA and (-)RNA viruses (B), retroviruses (C) and DNA viruses (D) (the schemes A-C were modified from: (Ahlquist, 2006).A: Following endocytosis, the genome of (+)RNA viruses may directly serve as mRNA for translation of virus encoded proteins. Among them, there are proteins of RNA-replication machinery that recruit (+)RNA into a membrane-associated replication complex. The genomic RNA is replicated by using (--)RNA template, which is transcribed in a low copy number Amplified (+)RNA is then packaged into newly assembled virions that exit the host cell either through secretion or cell lysis.B: Upon the virus attachment, a core containing both gRNA and virus encoded RNA polymerase is delivered into the cytoplasm by endocytosis. Cytoplasmic transcription of the (--)RNA template provides (+)RNA that serves as mRNA for translation of viral proteins. In dsRNA viruses, the (+)RNA is packaged into new cores which undergo maturation by synthesizing (--)RNA (dotted strand) and acquiring surface proteins. In the (--)RNA viruses, the (+)RNA strand is transcribed into genomic (--)RNA in the cytoplasm and then packaged. The new virions egress the cell either through secretion or cell lysis.C: Following fusion of viral and cell plasma membrane, the retroviral core is released into cytosol, RNA genome is transcribed into dsDNA by viral reverse transcriptase concomitantly with uncoating of the viral core, ds DNA is transferred into nucleus where it is integrated into host cell genome by viral integrase, following translation of retroviral structural and enzymatic polyproteins, the unspliced gRNA is packaged into the immature particles that usually assemble at the plasma membrane and the viral particles bud from the cell.D: Three mechanisms (I.-III.) of DNA viruses replication are shown: (I): Following entry and uncoating, the DNA genome is transported to the nucleus; products of early genes (regulatory proteins, transcription factors) regulate the synthesis of viral enzymes (e.g. DNA polymerase) required for genome replication; expression of late genes encoding structural capsid proteins in the cytosol, they are then transported into nucleus where packaging and pre-assembly take place; preassembled procapsids exit the nucleus and leave the cell (e.g. Herpesviruses). (II) unique replication cycle of Hepatitis B virus (HBV): following entry, the viral particle is internalized by endocytosis and the nucleocapsid is released into the cytoplasm; the genome (relaxed circular rcDNA) is transported into the nucleus, where it is converted to a covalently closed circular form (cccDNA); which serves as a template for transcription of pregenomic RNA (pgRNA) for translation of the core protein and the viral polymerase and three subgenomic mRNAs used for translation of regulatory and envelope proteins; following viral transcription and translation, the HBV core proteins self-assemble in the cytoplasm into viral nucleocapsid with concurrent incorporation of pgRNA and HBV polymerase, pgRNA is reversely transcribed into a rcDNA within the nucleocapsid; nucleocapsid containing rcDNA can either re-enter the nucleus to amplify cccDNA, or can be enveloped by HBV envelope proteins in the endoplasmic reticulum. The particles are then secreted from the infected hepatocyte by exocytosis. (III) Upon entering the cell, the replication, transcription and translation take place entirely in the cytoplasm, within discrete juxtanuclear sites called virus factories (e.g. poxviruses)Fig. 2Adapted from: Ahlquist, P., 2006. Parallels among positive-strand RNA viruses, reverse-transcribing viruses and double-stranded RNA viruses. Nat Rev Microbiol 4(5), 371-382.

The nature of the genome not only dictates the mechanism of replication, but also has other important consequences. The genome of (+)RNA viruses may serve directly as mRNA for production of viral proteins. Therefore, the mere introduction of genetic material (e.g. in exocytic vesicles) may result in productive infection. The RNA polymerases that copy the genetic material of RNA viruses are error-prone, which provides considerable genetic flexibility and the propensity to evolve drug-resistant mutants. These features are amplified in viruses with segmented genomes that undergo reassortment.

In viruses with segmented genomes (*Orthomyxoviridae*, *Arenaviridae* and *Bunyaviridae*), each segment is transcribed in an autonomous transcription-replication unit by viral RNA polymerase that binds to the 5′ end cap structure. Of note, the genomic RNA (gRNA) is capped by a unique mechanism called cap-snatching ([@bb0510]), in which the cap is cleaved from cellular mRNA and transferred onto the viral gRNA by a subunit of viral RNA polymerase ([@bb1370]). Some dsRNA viruses (*Birnaviridae* and *Reoviridae*) also contain segmented genomes. Upon replication, these viruses must ensure stoichiometric incorporation of single copies of each gRNA segment into new particles. This is guided by specific packaging signals on each segment of gRNA that interact with positively charged domains in the capsid proteins \[reviewed in ([@bb0800], [@bb1400])\]. Although different models of packaging have been proposed for various segmented genome viruses, a common feature is co-assembly of the capsid proteins with the gRNA and RNA polymerase.

### 2.4.2. Replication of DNA viruses {#s0050}

The genomes of DNA viruses come in a considerable variety of sizes and shapes, from small ss to large ds molecules that may be linear or circular. The size range of these genomes (from 1.8 kb to 1200 kb) reflects the necessity for some viruses to encode specific proteins required for viral replication. Small-genome DNA viruses (polyoma-, papilloma-, and parvoviruses) use only host cell enzymes for replication and transcription. The only exceptions are some hepadnaviruses (e.g. hepatitis B virus) that despite having small genomes (approximately 3 kb), encode their own specific DNA polymerase/reverse transcriptase that reverse transcribes pregenomic RNA (pgRNA) into genomic viral DNA ([Fig. 2](#f0010){ref-type="fig"}D, II) ([@bb0115]).

Viruses with intermediate-size genomes (up to 35 kb) (e.g. adenoviruses) encode their own DNA polymerase for genome replication, but they usually utilize cellular RNA polymerases II and III for transcription ([@bb0515]). Viruses with large genomes (larger than 100 kb) (e.g. herpesviruses) encode proteins for replication, including DNA polymerase and DNA helicase-primase, as well as some enzymes necessary for biosynthesis of deoxyribonucleotide triphosphates (dNTPs) and several transcription factors ([@bb0150]). Poxviruses (e.g. vaccinia virus), are another type of virus with large dsDNA genomes, and their replication, transcription, and translation take place entirely in the cytoplasm within discrete juxtanuclear sites called virus factories ([@bb1245]), ([Fig. 2](#f0010){ref-type="fig"}D, III). These viruses encode all enzymes and specific factors necessary for genomic replication and transcription. With their own replicative machinery, large-genome DNA viruses can replicate in nondividing cells. In contrast, the replication of small-genome DNA viruses, which depends on cellular DNA polymerases, must occur simultaneously with the S-phase of the cell cycle (e.g. parvoviruses), or must express some viral protein/oncogene to re-program the host cell-cycle regulatory proteins p53 or retinoblastoma protein (pRb), triggering entry into the S-phase (e.g. polyomaviruses and papillomaviruses). By affecting the G1/S checkpoint (controlled by p53 and pRb), the viruses ensure the production of host enzymes required for viral replication ([@bb0515]).

Production of viral proteins of DNA viruses with intermediate and large size genomes is divided into early and late phases. In the early (prereplicative) phase, nonstructural proteins required for DNA replication are translated. The late phase, during which the late structural proteins needed for assembly are translated, begins after viral DNA replication ([Fig. 2](#f0010){ref-type="fig"}D, I).

2.5. Assembly {#s0055}
-------------

Depending on the species, viruses assemble either in contact with the cellular membrane or independent of the membrane in either the nucleus or cytoplasm. The membrane-independent route is used by nonenveloped viruses and a few enveloped viruses (e.g. orthomyxoviruses, herpesviruses, and some retroviruses) that acquire the membrane envelope after intracellular assembly during budding from the cell.

### 2.5.1. Assembly in the nucleus {#s0060}

The limiting step for nuclear assembly is the size of NPCs, which are large enough to transport RNA and import proteins required for assembly into the nucleus; however, NPC size limits the transport of larger assemblies. Therefore, some viruses form assembly intermediates in the nucleus. These structures are then exported to the cytoplasm, where they come together to form viral particles. Nuclear export is specific and depends on the presence of nuclear export signals (NES) in the transported proteins. One example of a nonenveloped icosahedral virus that assembles in the nucleus is adenovirus, the assembly of which has been studied intensely due to its potential use in gene therapies \[reviewed in ([@bb0015])\]. Recent data suggest that upon accumulation of multiple copies of adenoviral dsDNA genomes, coordinated assembly and packaging occur by two interlinked mechanisms that involve both capsid proteins and core components ([@bb0360]). The assembly occurs in the so-called peripheral replicative zone with the assistance of scaffolding proteins that facilitate formation of adenoviral particles but are excluded from mature viruses. Adenoviruses are finally released upon lysis of the infected host cell.

Orthomyxoviruses and herpesviruses are enveloped viruses that assemble their nucleoproteins in the nucleus. Herpesviruses package their dsDNA genome as head-to-tail concatemers and assemble icosahedral procapsids on scaffold proteins in the nucleus \[reviewed in ([@bb0720])\]. However, subsequent steps of herpesvirus assembly proceed in the cytoplasm. The preassembled procapsid is too large to pass through the NPC, but it exits the nucleus by viral protein-driven vesicular transport across the nuclear inner membrane leaflet. Thus, the herpesvirus acquires an initial envelope from the inner nuclear membrane \[for review see ([@bb0515], [@bb0715])\]. Next, the herpesviral membrane fuses with the outer nuclear membrane, and the naked particle is released from the nucleus into the cytosol. Here, the virus acquires tegument (a protein layer between the capsid and the envelope) and other proteins. Final herpesvirus envelopment occurs at the Golgi membrane containing the viral glycoproteins ([@bb0515]). Preassembled orthomyxoviral ribonucleoproteins, upon their export from the nucleus, are driven to the plasma membrane to which they attach through electrostatic interactions of the matrix protein M1 with membrane phosphatidylserine. The virions then assemble simultaneously with budding during which they also acquire HA, NA and M2 membrane proteins. Poxviruses undergo an even more complicated pathway. They are enveloped with multiple membranes acquired from ER/intermediate compartments and Golgi or early endosomes ([@bb1250], [@bb1255]). These membranes also provide the poxviruses with their membrane proteins.

### 2.5.2. Assembly in the cytoplasm {#s0065}

Most viruses assemble upon interaction of their structural proteins with cellular membranes. The target membrane for assembly differs according to the virus type. Flaviviruses assemble at the surface of the ER and then upon their budding into the ER lumen, the immature particles are then transported into the TGN. Some viruses, such as coronaviruses, assemble at the ER--Golgi intermediate compartment \[reviewed in ([@bb1725])\]. The assembly of bunyaviruses occurs concurrently with replication of gRNA segments in virus factories located along the Golgi ([@bb0655], [@bb1615]). The presence of membrane glycoproteins at the Golgi membrane determines the sites where assembling bunyavirus particles bud into the Golgi lumen, similar to other enveloped viruses.

Numerous viruses, including paramyxoviruses ([@bb0375]), orthomyxoviruses ([@bb1400]), alphaviruses ([@bb0865]), rhabdoviruses ([@bb1305]), and most retroviruses ([@bb0530]), assemble underneath the cytoplasmic membrane, which facilitates assembly by providing a scaffolding function. The virus then acquires a lipid envelope through budding across the plasma membrane. During this process, it also gains the envelope glycoproteins (Env) that are anchored in the plasma membrane by hydrophobic transmembrane domains. Env reaches the plasma membrane by a cellular secretory pathway upon synthesis in the ER and subsequent glycosylation in the Golgi. Usually, a specific interaction between viral structural proteins and glycoproteins is required. This may be either direct or mediated through the interaction with matrix protein (e.g. in (--)RNA viruses such as ortho- and paramyxoviruses or rhabdoviruses). Most retroviruses, including HIV (so-called morphogenetic C-type), also assemble at the plasma membrane of the host cell. The interaction of the structural polyprotein precursor (Gag) with the plasma membrane is usually facilitated by a bipartite signal in the N-terminal domain of Gag (i.e. matrix protein) comprising both the basic patch and N-terminally linked myristoyl residue (added co-translationally to Gag). In contrast to C-type assembly at the membrane, morphogenetic B/D-type retroviruses assemble at pericentriolar sites where Gag polyproteins are transported along microtubules by dynein molecular motors ([@bb1560], [@bb1745]). For both morphogenetic pathways, the packaging of gRNA facilitates assembly.

(+)RNA viruses have adopted a mechanism of extensive rearrangement of intracellular membranes to provide a milieu for virus replication and assembly. This mechanism effectively protects dsRNA intermediates from degradation by the host cell machinery ([@bb0420], [@bb0805]). This process has been well-documented for poliovirus, in which the newly formed membranous structures exclusively serve for virus production. Various types of vesicles that are formed upon viral infection have different roles in viral replication ([@bb1490]).

Some nonenveloped mammalian viruses, such as reoviruses, assemble in the cytosol in so-called viroplasms or viral factories into icosahedral particles consisting of three concentric layers encircling segments of genomic dsDNA ([@bb0120], [@bb0860], [@bb1575]). Rotavirus seems to be the only exemption in the reovirus family, as it enters the endoplasmic reticulum to gain its outer protein shell ([@bb1710]).

2.6. Maturation {#s0070}
---------------

Numerous viruses assemble from polyprotein precursors that must be specifically cleaved by a viral protease to generate infectious particles. This mechanism, which is an irreversible step in the virus life cycle, ensures equimolar packaging of structural proteins and proportional co-assembly of viral enzymes in the form of precursors. Upon proteolytic release, the liberated proteins may undergo different trafficking pathways or fulfill various functions in the virus. Maturation changes the energy of interaction forces among those interfaces required for intracellular assembly of immature particles to those suitable for viral stability in the environment and for disassembly and uncoating of genetic material for replication \[reviewed in ([@bb1740])\].

In poliovirus, the autocatalytic and subsequent viral protease-mediated cleavage of P1 precursor protein allows formation of pentamers that interact with gRNA. Additional cleavage of VP0, yielding VP2 and VP4, is required to form infectious poliovirus particles. In retroviruses, proteolytic processing is initiated by the autocatalytic liberation of viral protease, which subsequently cleaves the polyproteins to trigger major structural rearrangements in the virus and release of other viral enzymes (reverse transcriptase and integrase) and structural proteins.

In herpesviruses, maturation involves proteolytic processing of the scaffolding protein and recruitment of tegument proteins that stabilize the particle and mediate interactions with the membrane during envelopment ([@bb0580], [@bb1655], [@bb1660]).

Adenoviruses undergo a maturation process that involves processing of six structural components of the core and one non-structural precursor that initiates replication of gDNA ([@bb0555]). One interesting feature of adenoviral maturation is that DNA is required as a co-factor for protease activity. This means that maturation occurs only in particles that have packaged gDNA ([@bb1150]).

Flaviviruses form icosahedral particles upon budding into the neutral milieu of the ER. The particles then translocate to the more acidic environment of the trans-Golgi network. This pH shift results in disassembly of the immature lattice and extensive rearrangement of the flaviviral particle. This is connected with the exposure of a viral structural glycoprotein (prM) that is specifically processed by the cellular protease furin in the trans-Golgi network. The liberated globular heads of prM remain attached at the low pH, but are released when the virus enters neutral body fluids ([@bb1470]).

2.7. Release {#s0075}
------------

One frequently used mechanism of release of nonenveloped and some enveloped viruses is lysis of the infected cell. This is the simplest release mechanism, although the transition to lysis from latent infection is delicately regulated ([@bb0055], [@bb1025], [@bb1535]). However, viruses that are usually lysogenic may also use alternative release pathways ([@bb0130]). These include non-lytic spread of viruses mediated by vesicles, which has been observed for poliovirus ([@bb0135], [@bb0810]), coxsackievirus ([@bb0025]), and hepatitis A virus ([@bb0500]). Another possibility is that vesicles released from a cell infected with (+)RNA viruses contain naked viral gRNA. This (+)gRNA-containing vesicle functions itself as an infectious agent as it is transferred to another cell ([@bb0130]).

The standard way for enveloped viruses to leave the host cell is budding, which includes membrane extrusion and separation of the viral and cellular membranes (so-called pinching off). The lipid envelope layer acquired during viral particle budding through the plasma membrane protects the virus particle. There are three basic mechanisms of budding: i) mediated by envelope glycoproteins, such as the E protein of coronaviruses; ii) independent of glycoproteins, in which the viral structural proteins trigger the extrusion of the plasma membrane, such as retroviral budding in which strong interactions between the Gag N-terminal domain (matrix protein) and the plasma membrane induce bulging of the membrane; and iii) requiring interaction between the viral glycoproteins and the capsid for membrane extrusion, as in alphaviruses.

The final step that results in the separation of virus from the cell surface is pinching off the particle. This is a controlled process that involves both viral protein domains and cellular factors. During this process, viruses apparently use cellular machinery similar to that used during the last step of cell division (the release of the daughter cell) called endosomal sorting complex required for transport (ESCRT) \[reviewed in ([@bb0235], [@bb0780], [@bb1310], [@bb1545])\]. Direct interactions of numerous viral domains with ESCRT complex subunits have been identified ([@bb0125]). In retroviruses, short specific amino acid sequences (PTAP or PSAP) interact with the ESCRT components, and the interaction of HIV with the ESCRT proteins Nedd4 and Alix is well-known ([@bb0525], [@bb0550], [@bb0595]). However, this mechanism has also been adopted by other viruses that interact with the same ESCRT components, such as filoviruses ([@bb0695], [@bb0830], [@bb1080]). Interactions with ESCRT proteins have also been reported for vesicular stomatitis virus ([@bb0285], [@bb1125]), rhabdovirus ([@bb1675]), arenaviruses ([@bb1920]), picornaviruses ([@bb0500]), paramyxoviruses ([@bb1335]), and hepatitis C virus, a representative of the flavivirus family ([@bb0480]).

The typical release pathways used by viruses may vary under some conditions. For example, during chronic infection, numerous viruses use alternative cell-to-cell transmission that may help the virus avoid host neutralization ([@bb0775]). Syncytium formation, an HIV-induced cell fusion, was recognized in the early 1990s ([@bb0200]). Another type of cell-to-cell transmission through tight junctions was shown for HIV ([@bb0765], [@bb1795]) and murine leukemia virus ([@bb1580]). Receptors on tight junctions that specifically recognize hepatitis C virus ([@bb0245], [@bb1390]) and reovirus ([@bb0085]) have been identified. Some viruses are able to modify cellular pathways to reprogram both the synthesis and metabolism of lipids and membrane compartmentalization for their transmission and to evade cellular defense mechanisms ([@bb1175]). Despite a general understanding that poliovirus spreads through cellular lysis, it was recently found that it may also be transferred between cells by an autophagy-dependent mechanism, called autophagosome-mediated exit without lysis ([@bb0135], [@bb0140], [@bb0970], [@bb1480]). Similar mechanisms have been described for varicella-zoster virus and human cytomegalovirus ([@bb0630], [@bb1185]). Poxviruses encode several proteins that block the apoptotic cellular response to the presence of their dsDNA in the cytoplasm. This allows cell-to-cell passage of poxviruses by a mechanism known as apoptotic mimicry ([@bb0035], [@bb1285]). In this process, enveloped viruses expose surface phosphatidylserine to mimic apoptotic bodies. These cells are then macropinocytosed by either dendritic cells or macrophages ([@bb1205]).

3. Methods {#s0080}
==========

Among the plethora of compounds designed to inhibit infectious viruses, only a few (\< 100) have been approved for clinical use ([@bb0395], [@bb0400]). Nevertheless, some effective antiviral drugs have been on the market for several decades, such as the anti-influenza A virus drug amantadine, marketed under the trade name Symmetrel (by Dupont), which was approved in 1966. In 1982, Burroughs-Wellcome introduced acyclovir as an inhibitor of herpesviruses. Its remarkable specificity is connected with its activation by viral thymidine kinase-catalyzed phosphorylation. However, due to development of drug resistance in a number of viruses, especially RNA viruses, there is a continuous need to design and test new inhibitors, preferably targeting different steps of viral life cycles. Here, we provide insights into the world of biochemical and cell-based assays that were developed to test antivirotics targeting various steps in the viral life cycle.

3.1. Assays and methods for screening and evaluating viral entry inhibitors {#s0085}
---------------------------------------------------------------------------

Different types of assays, including cell-cell fusion assays, cell-virus fusion assays with pseudotyped viral particles, and *in vitro* biochemical assays have been developed to screen inhibitors of viral entry. In enveloped viruses, entry is initiated by fusion of the viral envelope with the target cellular membrane. The entry mechanism has been well-described for HIV-1, in which it is mediated by Env glycoprotein, consisting of transmembrane gp41 and surface gp120 subunits. Binding of gp120 to its cellular receptor, CD4, and to one of two co-receptors, CXCR4 or CCR5, triggers a refolding of gp41 that promotes fusion of the viral and cellular membranes. The refolding involves oligomerization of the extracellular N- and C-terminal heptad repeat (HR) domains of gp41, which leads to the formation of a 6-helical bundle \[reviewed in ([@bb1190])\].

Jiang et al. established an *in vitro* system to quantify formation of the HIV-1 gp41 6-helical bundle ([@bb0850]). In their system, the bundle is formed by mixing equimolar concentrations of peptides derived from the N- and C-HR regions of gp41. ELISA using the monoclonal antibody NC-1, which specifically recognizes and binds an epitope formed on the gp41 6-helix bundle but not the individual peptides, enables screening for compounds that prevent formation of fusion-active gp41. For HTS of HIV-1 fusion inhibitors, this method was modified to use a fluorescence-linked immunosorbent assay (FLISA), in which the C-HR peptide was replaced with FITC-conjugated C-HR peptide ([@bb1085])**.**

Cell-based assays are routinely used to screen viral entry inhibitors. High throughput formats have been developed for screening of HIV-1 fusion inhibitors. Cell-cell fusion assays involve two types of cells: effector cells that stably ([@bb0170]) or inducibly ([@bb0725], [@bb0845]) express HIV-Env glycoprotein and target cells that express CD4 and either CXCR4 or CCR5. Co-cultivation of these cells leads to HIV-1 Env-mediated cell membrane fusion, resulting in formation of multinucleated syncytia. Membrane fusion induces expression of a reporter protein such as luciferase ([@bb0725], [@bb0845]) or β-galactosidase ([@bb0170]). One such assay enables determination of both the efficiency and specificity of fusion inhibitors ([@bb0725]). This approach uses effector cells that express both HIV-1 Env and the Renilla luciferase (R-Luc) reporter protein using inducible tetracycline-controlled transactivator (tTA) and target cells that express the HIV-1 receptor (CD4) and co-receptor (CCR5) and contain the firefly luciferase (F-Luc) reporter gene under the control of a tTA-responsive promoter. Upon fusion of the effector and target cells, tTA enters the target cells and activates the expression of the F-Luc reporter. The inhibition of fusion of cellular membranes is determined as a decrease in F-Luc luminescence, and the inhibitor specificity is measured as the R-Luc activity ([@bb0725]).

Based on an HIV-1 cell-cell fusion method that uses a computer-controlled digital image analysis system for automatic quantitation ([@bb1100]), a modified method was developed to screen inhibitors targeting MERS-CoV S protein ([@bb1105]). To test potential fusion inhibitors, effector cells stably expressing the MERS-CoV spike protein S2S and EGFP were used to mediate fusion with target cells expressing the DPP4 receptor ([@bb1105]).

Virion-based fusion assays are another category of cell-based fusion assays. One such approach is based on production of chimeric HIV-1 virions carrying β-lactamase--Vpr chimeric protein (BlaM-Vpr). Chimeric HIV released into the cell culture media is isolated by ultracentrifugation and used to infect target cells. Entry of the virions into the cytoplasm is detected by cleavage of a fluorescent substrate by β-lactamase. The fluorescence shift corresponds to the fusion efficacy and is measurable by fluorescence microscopy, flow cytometry, or fluorometric plate reader ([@bb0260], [@bb0265], [@bb0270]). Modification of this assay by constructing pseudotyped HIV-1 virions in which HIV-1 Env was replaced with Ebola virus glycoprotein (GP) has also been described ([@bb1845]). Tscherne et al. developed an approach to monitor viral entry using the BlaM reporter ([@bb1715]). Their assay uses influenza virus-like particles (VLPs) bearing the influenza membrane proteins hemagglutinin and neuraminidase. BlaM tagged with influenza matrix protein (M1) is incorporated into the VLPs and delivered into target cells. Upon release, BlaM can be detected by flow cytometry, microscopically, or fluorometrically.

A rapid cell-based HTS method was developed to assess SARS-CoV entry inhibitors ([@bb1905]). This Dual Envelope Pseudovirion (DEP) assay employs two HIV pseudoviruses: one encodes an envelope protein from the target virus and firefly luciferase and the second encodes a control, unrelated viral envelope protein and Renilla luciferase. Reporter expression is determined with the Dual-Glo Luciferase Assay System (Promega). Inclusion of the unrelated envelope protein greatly reduced false positive hits ([@bb1905]). The method was further used to screen compounds that inhibit entry of filoviruses, including Ebola virus ([@bb1915]). A similar approach employing four pseudotyped HIV viruses, carrying Marburg virus glycoprotein, hemagglutinin and neuraminidase isolated from A/Goose/Qinghai/59/05 (H5N1) influenza virus, Ebolavirus Zaire envelope glycoprotein, and Lassa virus envelope glycoprotein, has been used for entry inhibitor screening ([@bb0295]). This screening identified multiple compounds with potent inhibitory activity against entry of both Marburg and Ebola viruses in human cancer cell lines, and confirmed their anti-Ebola activity in human primary cells ([@bb0295]). Other pseudotyped viral assays have been used to screen entry inhibitors of SARS-CoV, Ebola, Hendra, and Nipah viruses. To establish infection, the glycoproteins of these viruses must be processed by the host intracellular lysosomal protease cathepsin L (CatL). HTS resulted in identification of several inhibitors that block the cleavage of viral glycoprotein but not CatL itself ([@bb0465]).

Until recently, the development of anti-HBV therapeutics had been limited by the lack of an *in vitro* infection system. Several aspects of the HBV life cycle have been elucidated using *in vitro* production of HBV particles after transfection of human hepatoma cell lines (HepG2) with recombinant HBV DNA and by establishment of hepatoma cell lines with the entire HBV genome integrated, such as the HepG2.2.15 cell line ([@bb0965], [@bb1550], [@bb1645]). In addition to differentiated human (PHHs) ([@bb0610]) and *Tupaia belangeri* ([@bb0585]) hepatocytes, the HepaRG cell line, which exhibits hepatocyte-like characteristics, also supports HBV replication ([@bb0615]). The identification of sodium taurocholate cotransporting polypeptide (NTCP) as an HBV receptor by Yan et al. opened possibilities to use NTCP-complemented HepG2 cells not only for studies of HBV replication mechanisms but also for HTS of inhibitors ([@bb1825])**.**

In an infection competition assay, HBV particles were isolated and used to infect HepaRG and PHHs cells that had been pre-incubated with HBV envelope protein-derived peptides to test their potential activity to block HBV infection. Twelve days after infection, viral RNAs were quantified by Northern blot ([@bb0615], [@bb0620]). Using this assay, researchers identified a peptide that specifically prevents HBV and HDV entry into HepaRG and PHHs cell lines ([@bb0620]), primary cultures of tupaia hepatocytes ([@bb0590]), and cells *in vivo* ([@bb1120], [@bb1365], [@bb1755]). Recently, a Phase IIa clinical trial of a first-in-class entry inhibitor (myrcludex-B) that functions as an NTCP inhibitor was promisingly completed ([@bb0155]).

Development of cell culture systems producing HCV pseudoparticles (HCVpp) and infectious HCV particles (HCVcc) has shed light on HCV interactions and enabled discovery of antiviral drugs and vaccines ([@bb0355]). HCVpp consist of HCV E1 and E2 glycoproteins enveloping a retroviral particle that packages *GFP* mRNA during assembly ([@bb0090]). The entry efficiency of HCVpp can be quantified by FACS analysis as the number of GFP-positive cells. Use of this screening system led to discovery of a triazine derivative that blocks the entry of HCV ([@bb0080]).

Production of HCVcc is a robust system to generate infectious HCV in naïve cells ([@bb0885], [@bb1900]). The anti-HCV activity of hundreds of compounds approved for a wide variety of indications was determined immunochemically with anti-HCV E2 antibody in 96-well plate format. Over thirty compounds displayed anti-HCV activities, most of which were directed against HCV entry ([@bb0565]).

3.2. Assays and methods for screening viral capsid disassembly/uncoating inhibitors {#s0090}
-----------------------------------------------------------------------------------

The majority of viruses enter cells by endocytosis. Unfortunately, there are no suitable experimental techniques for endosome handling, making it difficult to study early steps in the viral life cycle such as uncoating and capsid disassembly. Viruses that enter cells by direct membrane fusion, such as HIV-1, are an exception. There are several methods available to monitor and quantify HIV uncoating. As some of these were reviewed recently by Campbell and Hope ([@bb0210]), we will discuss them very briefly. Two main techniques are used in these assays: ultracentrifugation or utilization of HIV-1 specific cellular restriction factors. The "*in vitro* core-stability assay" is based on ultracentrifugation of released HIV-1 virions through a detergent layer, where the viral membrane dissolves, into a sucrose gradient, where the viral cores are concentrated ([@bb1570]). The "fate of capsid" assay uses ultracentrifugation through a sucrose cushion to separate the HIV-1 core from a whole cell lysate prepared shortly after infection ([@bb1625]). The "CsA-washout assay" involves specific cellular factors (TRIM-cyclophilin) that restrict HIV-1 infection by binding to the capsid core and cyclosporine A (CsA), which can effectively turn off restriction ([@bb0770]). Recently, a novel entry/uncoating assay (EURT), an alternative to BlaM-Vpr (described in [Section 3.1](#s0085){ref-type="sec"}), was reported ([@bb0385]). It quantifies the protein product of a virion-packaged mRNA reporter upon uncoating.

A method to monitor the uncoating/disassembly of the capsid of influenza A virus, which enters the cell by endocytosis, also is based on ultracentrifugation ([@bb1605]). Purified virions are separated using velocity gradient centrifugation through a two-layer glycerol gradient. Similar to the "*in vitro* core stability" assay for HIV, the sedimenting viruses migrate through the detergent-containing layer of the gradient, which dissolves the membrane to release the viral core. Moreover, modification of the detergent-containing glycerol layer---for example, by lowering pH, changing ionic strength, or adding putative viral uncoating factors---enables study of the factors or compounds that affect viral uncoating *in vitro*.

3.3. Assays and methods for screening and evaluating viral genome replication inhibitors {#s0095}
----------------------------------------------------------------------------------------

### 3.3.1. Polymerases {#s0100}

Depending on the virus type, either DNA or RNA polymerases replicate the viral genome. Thus, these enzymes play a key role in viral life cycles. Reverse transcriptase, an RNA-dependent DNA polymerase of retro- and hepadnaviruses, is unique among nucleic acid polymerases. Despite the different mechanisms of viral replication, polymerases, which are essential for all viruses, are excellent targets for antiviral therapies.

Polymerase inhibitors represent the vast majority of clinically approved antiviral drugs, followed by protease inhibitors, immunostimulators, entry inhibitors, and integrase inhibitors \[reviewed in ([@bb0400])\]. Polymerases continue to be a preferred target for newly designed inhibitors ([@bb0320], [@bb0400]). Polymerase inhibitors may be nucleoside and nucleotide analogs, pyrophosphate analogs, or nonnucleosides, such as allosteric inhibitors ([@bb0400], [@bb1290]). Non-specific approaches such as plaque assays were initially used to monitor the effectiveness of polymerase inhibitors ([@bb1690], [@bb1695]). The activity of these inhibitors also can be evaluated based on their ability to prevent the cytopathic effects of the virus ([@bb1880]). More straightforward assays involve measurement of incorporated radio-labeled nucleotides, which directly reflects the polymerase activity ([@bb0330], [@bb0740], [@bb0875]); these include HTS methods using homopolymeric polycytidylic acid and \[^3^H\]-GTP ([@bb0045]). Alternatively, the pyrophosphate released during the polymerase reaction can be measured luminometrically by combining the primer extension with the commercial PiPer assay ([@bb1145]). The pyrophosphate anion also can be detected with DNA-attached magnetic nanoparticles ([@bb1705]) or quantum dots ([@bb0275]). Frequently used fluorescence methods avoid the use of radiochemicals. These methods exploit a fluorescent label, such as dsDNA binding dyes like SYBR green or PicoGreen ([@bb0445], [@bb0750], [@bb1925]), or FRET between two nucleotides ([@bb1540], [@bb1800]). Numerous kits for quantification of products of both DNA and RNA polymerases, including reverse transcriptase, are commercially available ([@bb0195]). Quantitative real-time PCR is a preferred method to monitor the activity of DNA polymerases (cellular as well as viral) in the presence of inhibitors ([@bb0110], [@bb1935]), and quantitative real-time reverse-transcription PCR has become standard for screening inhibitors of viral RNA polymerases ([@bb1005], [@bb1300], [@bb1360], [@bb1880]). White et al. described a HTS method using a microfluidic apparatus combined with digital PCR for single-cell analysis ([@bb1805]). In their method, a fluorescently labeled template also serves as a primer, due to stem formation. It emits a measurable polarization signal both upon binding of the polymerase and extension ([@bb1215]). The assay has been used for HTS of inhibitors of poliovirus RNA polymerase ([@bb0205]).

When available, viral genomes modified with reporter genes can be used for cell-based luminescent or fluorescent screening of viral inhibitors ([@bb0110], [@bb0455], [@bb0495], [@bb0505], [@bb1090], [@bb1140], [@bb1785]). This approach can be extended to screen inhibitors of other enzymes. In the aptamer-based approach, a DNA template encodes RNA of interest joined to a fluorescence module and ribozyme sequence. When transcribed, the fluorescence module is released and detected ([@bb0745]).

HCV uses an RNA-dependent RNA polymerase (RdRp). A unique cell-based assay for monitoring HCV RNA polymerase (NS5B) activity, based on the innate immune signaling molecule retionic acid-inducible gene I product (RIG-I), has been developed ([@bb1445]). The RIG-I-like receptors are cytosolic proteins that recognize viral RNA and induce production of proinflammatory cytokines and interferon-activated genes ([@bb0840]). RIG-I triggers cytokine production stimulated by various viral RNAs from different families, including *Flaviviridae*, *Paramyxoviridae*, *Rhabdoviridae*, *Orthomyxoviridae*, and *Arenaviridae*, as well as Ebola virus RNA ([@bb0840]). The assay is based on recognition of HCV RNA produced by active NS5B by RIG-I, followed by RIG-I-mediated activation of firefly luciferase expression controlled by the interferon b promoter. Renilla luciferase expression is used for normalization of transfection efficacy.

### 3.3.2. Methyltransferases {#s0105}

The viral gRNAs of some RNA viruses are modified at the 5′ ends with cap structures, which may be either acquired from the host cell mRNA (e.g. in influenza virus) or newly synthesized (e.g. flaviviruses). The methylation of viral gRNA mimics that of cellular mRNA cap structures to enhance the chances of the virus to escape from cellular defense mechanisms and also to increase the efficiency of translation of viral proteins. Virus-specific methyltransferases are thus a promising therapeutic target.

Virus-encoded methyltransferases have been identified and characterized in flaviviruses such as Zika virus ([@bb0350], [@bb0370], [@bb0450], [@bb1265], [@bb1895]), West Nile virus, and dengue virus ([@bb0440]); rhabdoviruses such as vesicular stomatitis virus (VSV) ([@bb1435]); coronaviruses such as SARS ([@bb1780]); and roniviruses ([@bb1865]). In flaviviruses, the N-terminal part of NS5 methyltransferase catalyzes cap formation *via* both guanine N-7 and ribose 2′-OH methylations at the 5′ end of gRNA, and the C-terminus of the enzyme is responsible for the RNA polymerase activity ([@bb1460], [@bb1890]). The C-terminal part of the SARS nsp14 protein exhibits guanine N7-methyltransferase activity, forming the gRNA cap, while the 3′-5′ exoribonuclease activity of the N-terminus enhances the fidelity of viral replication ([@bb0250], [@bb1230]). In VSV, the methyltransferase activity resides in the conserved region VI of the multifunctional large polymerase protein ([@bb1035], [@bb1135]).

Some cellular methyltransferases regulate viral infections, as shown for herpes simplex virus, for which epigenetic control is involved in viral latency ([@bb0325]). Inhibition of human histone methyltransferases such as histone-lysine N-methyltransferase (EZH2/1) ([@bb0070]) or lysine-specific demethylase-1 (LSD1) induces antiviral signaling pathways ([@bb1055]). The inhibitory effect of histone demethylase activity has been demonstrated for human cytomegalovirus ([@bb0560]) and herpes simplex virus ([@bb0730], [@bb1060]).

The activity of purified recombinant methyltransferases can be determined by measuring the methylation by-product S-adenosyl homocysteine (SAH) using commercially available kits. In one such assay, conversion of S-adenosyl methionine (SAM) to SAH is monitored luminometrically *via* luciferase reaction, in which measurable ATP is generated through a sequence of reactions with MTase-Glo™ reagent (Promega). The EPIgeneous™ methyltransferase kit (CisBio Bioassays) is based on competition of produced SAH with fluorescently labeled SAH (SAH-d2 tracer) for binding to a terbium cryptate-labeled anti-SAH antibody. The decrease in FRET between the tracer and antibody is then evaluated. ELISA using anti-5-methylcytosine antibody can be used to quantify methylation of immobilized cytosine-rich DNA substrate (e.g. EpiQuik™ DNA Methyltransferase Activity/Inhibition Assay Kit; Epigentek). This method was modified with homogenous time resolved FRET ([@bb0410]) to screen a library of inhibitors against SARS-CoV nsp14 ([@bb0065]).

Flaviviral and human cap N7-MTases have been screened with radioactive assays using ^3^H-labeled SAM and GpppAC4 or ^7m^GpppAC4 synthetic RNAs. The ^3^H methyl transferred onto DEAE filter-bound RNA can be measured by scintillation after multiple washings to remove unincorporated ^3^H-SAM ([@bb0370]). Alternatively, *in vitro* transcription can be carried out using ^3^H-SAM. The radioactively labeled products are then resolved by thin-layer chromatography and developed using a phosphorimager ([@bb1040]).

A yeast cell-based method was established based on the finding that coronavirus methyltransferase can functionally replace a methyltransferase essential for yeast viability ([@bb0280], [@bb1640]). In this method, Sun *et al*. constructed recombinant yeasts producing the viral methyltransferase instead of the yeast one ([@bb1640]). This strain was used for a HTS of methyltransferase inhibitor activity that negatively correlated with the cell density after 20 h incubation.

### 3.3.3. Helicases {#s0110}

Virus-encoded ATPase-driven helicases have been identified in numerous human pathogens. Helicases from several (+)RNA viruses have been characterized, including NS3 helicases from flaviviruses such as dengue virus, HCV, West Nile virus, yellow fever virus, and Japanese encephalitis virus ([@bb0240], [@bb0645], [@bb0820], [@bb1070], [@bb1275], [@bb1810]). SARS and MERS coronaviruses encode nsp13 with helicase activity ([@bb0005], [@bb0700], [@bb1555]). In Semliki Forest virus, a representative member of the togavirus family, helicase activity is encoded by the N-terminal domain of nsP2 protein. Helicases are also common in some DNA viruses, including poxviruses. These include the vaccinia virus helicase-primase D5 ([@bb0105], [@bb0790]), E1 protein of bovine papilloma virus 1 ([@bb1830]), and the large tumor antigen of SV40 ([@bb1600]). Helicases appear to be attractive targets for antiviral drugs ([@bb0180], [@bb0535], [@bb1475]), but development of such compounds is challenged by cytotoxicity and bioavailability issues ([@bb0960]).

Traditional methods for monitoring the activity of RNA helicases use radioactively labeled dsRNA substrates and follow the unwinding reaction by electrophoretic separation (nondenaturing PAGE) of the ss reaction products, which are detected autoradiographically ([@bb0010], [@bb1735]). To determine whether the inhibitor affects binding of helicase to nucleic acid, a standard gel mobility shift assay is usually used ([@bb0010]).

Helicase activity is fueled by ATP hydrolysis; thus, inhibition of ATPase activity became another possible antiviral strategy. ATPase activity can be determined either by the decrease in ATP or formation of ADP (using commercially available fluorescent anti-ADP antibodies) or inorganic pyrophosphate. Phosphates released by ATP hydrolysis can form a molybdophosphate complex that can be measured colorimetrically using malachite green, quinaldine red, or rhodamine B ([@bb0100], [@bb0405], [@bb1235]) or by light-scattering ([@bb1320]). The colorimetric methods can be miniaturized for HTS ([@bb1930]). The absorbance-based assay was also converted into a HTS method based on fluorescence quenching by a colored quinaldine red complex ([@bb1235]). An alternative method employs a europium--tetracycline complex for luminescent determination of inorganic phosphate ([@bb1530]). A more complex coupled enzyme colorimetric assay (with maltose phosphorylase, glucose oxidase, and horseradish peroxidase) was used for HTS of ATPase inhibitors ([@bb0075]). Assays for luminescent and fluorescent screening of ATPase activity, including an immunochemical method using fluorescently labeled anti-ADP antibodies, have been reviewed by Shadrick and colleagues ([@bb1565]). In a radioactive method using \[γ-^32^P\]ATP, the AMP product was separated from unreacted ATP by thin-layer chromatography on polyethyleneimine-cellulose and visualized autoradiographically ([@bb0010]).

Several research groups have described fluorescence assays to identify inhibitors targeting SARS-CoV helicase (nsp13) ([@bb0010], [@bb0305], [@bb1325]). The substrate is usually a dsDNA oligonucleotide consisting of a fluorescently labeled strand annealed to the complementary strand carrying a quencher. This approach was also adapted for real-time determination of the RNA helicase activity of HCV ([@bb1665]). In this assay, an ssDNA capture strand complementary to the strand carrying the quencher was used to prevent reannealing of the unwound duplex. Recently, a colorimetric assay for monitoring helicase activity using DNA-conjugated gold nanoparticles was developed ([@bb0415]). This method is based on shifts in the optical properties of nanoparticles due to DNA unwinding and allows simple screening of inhibitor activity. The dsDNA melting curves can be determined spectrophotometrically (at 524 nm and 260 nm) or even by the naked eye. Another fluorescence HTS of dengue virus NS3 helicase inhibitors measures the unwinding of a double-labeled molecular beacon ([@bb0095]). Other approaches involve graphene oxide-based fluorescence monitoring of viral helicase activity \[reviewed in ([@bb0825])\]. A G-quadruplex-based method for label-free determination of HCV helicase NS3 activity measures changes in the luminescence of transition metal complexes with DNA upon helicase-mediated quadruplex melting ([@bb1020]).

### 3.3.4. Kinases {#s0115}

Both protein tyrosine kinases and protein serine/threonine (S/T) kinases have been found in viruses. Tyrosine kinase function is well-understood in connection with oncogenic retroviruses, \[for review on retroviral oncogenes, see ([@bb1750])\]. In contrast to tyrosine kinases from oncogenic viruses, such as Rous sarcoma virus src tyrosine kinase, viral S/T kinases share little homology with cellular enzymes. They are exclusively encoded by large DNA viruses (e.g. herpesviruses), in which they play important roles in viral virulence, helping the virus to escape defense mechanisms such as those regulated by cytokine signaling pathways ([@bb0815], [@bb1525]). Their autophosphorylation and transphosphorylation activities mimic those of cellular cyclin-dependent kinases such as cdc2. For example, viral kinases can phosphorylate translation elongation factor 1 delta (EF-1δ) ([@bb0815], [@bb0900]). All herpesviruses encode the S/T protein kinase UL13, and US3 S/T kinases have been described in the alphaherpesvirus subfamily ([@bb0880], [@bb0900]).

In addition to protein kinases, HSV encodes a thymidine kinase. Unlike cellular thymidine kinase, HSV thymidine kinase has a wide substrate specificity that includes pyrimidine and purine phosphonate analogs (e.g. acyclovir, ganciclovir, penciclovir) ([@bb0400]). In the body, ganciclovir is phosphorylated by cellular kinases and penciclovir and acyclovir by virus-encoded thymidine kinases to the active nucleoside triphosphate forms of the drugs that inhibit viral DNA synthesis ([@bb0400], [@bb0930]).

Some cellular protein kinases appear to support viral replication. For example, polo-like kinases induce early stages in the influenza virus life cycle ([@bb1405]), and human protein kinase C regulates the assembly of the ribonucleoprotein complexes in influenza virus ([@bb1240]). Inhibitors of Abelson tyrosine-protein kinase 2 are active against SARS and MERS coronaviruses ([@bb0345]). Several *in vitro* approaches can be used to determine kinase activity as well as the activity of kinase inhibitors.

Analyses of the cellular phosphoproteome, sometimes accompanied by phosphopeptide enrichment, have become standard to determine kinase activity ([@bb0990], [@bb1220], [@bb1760]). These assays can be used to assess the impact of inhibitors on the overall phosphoproteome in mammalian cells. Although these methods provide complex information about the overall array of kinases and phosphatases in the cell ([@bb1315]), they are not applicable to screening inhibitors of a single viral kinase. For these purposes, *in vitro* assays with recombinant kinases have been developed \[for review see ([@bb1130])\], including some HTS fluorescence methods ([@bb1855]) that can replace radioactive techniques using \[γ^32^P\]ATP ([@bb1520]). Mass spectrometric analysis also can be used to identify *in vitro* kinase inhibitors. For these analyses, synthetic peptides, proteins, or phosphatase- and heat-treated tissue samples (to dephosphorylate the proteins and inactivate all enzymes, respectively) are subjected to kinase treatment in the presence of inhibitors ([@bb0760], [@bb1220], [@bb1820]).

Recombinant kinase activity in the presence of inhibitors can be quantified as ATP consumption or ADP production in the phosphorylation reaction by numerous commercial kits. Other methods monitor binding of inhibitors to phage-displayed kinases in ligand competition assays ([@bb0475]).

Fluorescence methods including FRET, fluorescence polarization or intensity endpoint measurement, and lifetime imaging of fluorescence ([@bb1045]) including fluorescence biosensors ([@bb1870]) have been reviewed elsewhere. Sulfonamido-oxine labeled peptides can be used as chromophores that bind Mg^2 +^ upon phosphorylation and emit chelation-enhanced fluorescence ([@bb0425], [@bb1115]). Kinase-catalyzed phosphorylation of fluorescent peptides promotes their binding to metal-coated nanoparticles, which decreases their mobility and enhances measurable fluorescence polarization ([@bb0990], [@bb1590]). TbIII complexes, in which phosphotyrosine induces fluorescence emission ([@bb1775]), may be used to evaluate protein tyrosine kinase activity ([@bb0020], [@bb1635]). Fluorescence polarization methods also can be useful for drug screening \[reviewed in ([@bb0675])\]. Other alternatives are immunochemical methods that use antibodies specific to the phosphorylated amino acids, such as phosphotyrosine ([@bb1030], [@bb1850]) or phosphoserine/phosphothreonine. These antibodies can be used to detect protein/peptide phosphorylation by Western blotting, ELISA, or immunoprecipitation of phosphorylated proteins for further mass spectrometry-based analysis ([@bb0625], [@bb1875]). An elegant approach that limits the false-positive hits in screening of specific kinase inhibitors is based on an *in situ* proximity ligation assay using both an antibody against the target protein and an anti-phosphotyrosine antibody ([@bb1015]). Both antibodies are coupled with oligonucleotides, which when brought together due to antibody binding, can be enzymatically ligated and replicated through rolling circle amplification to form a long linear tandem repeat of sequences detectable by a complementary fluorescent oligonucleotide.

In addition to protein kinases, some lipid kinases have been targeted by antivirals. One example is sphingosine kinase 1, which affects replication of dengue virus ([@bb0030]). Its activity can be determined by measuring the production of ^32^P-labeled sphingosine-1-phosphate from sphingosine and \[γ^32^P\]ATP ([@bb0310], [@bb1385]).

### 3.3.5. Integrase {#s0120}

Retroviral integrase inhibitors are a new type approved new type of inhibitors imposed by the emergence of drug-resistant mutants. HIV integrase activities, integrase inhibitors, and drug resistance have been discussed in detail elsewhere ([@bb0050], [@bb0060], [@bb0670], [@bb1065], [@bb1395], [@bb1685]). Methods to assess the two major activities of integrase---end processing of the reverse transcription product and its joining to target chromosomal DNA---have been reviewed in detail by several groups ([@bb0470], [@bb1155], [@bb1210]). Initial methods used radioactively labeled DNA oligonucleotides comprising the terminal *cis*-acting sequences of linear viral DNA required for integration. The joining of the processed strand to the other strand (self-integration) or to supplemented target DNAs can be analyzed by PAGE ([@bb0890], [@bb0895]). A less time-consuming, non-radioactive method involves time-resolved fluorescence anisotropy measurement using a 21-meric oligonucleotide fluorescently labeled on the terminal GT dinucleotide. This assay monitors the binding of integrase to the substrate as well as the subsequent 3′-processing reaction, which both change the anisotropy ([@bb0650]). Alternatively, the yields of both the processing and joining reactions can be measured upon separation of the radioactively labeled product from the rest of the DNA molecule using adsorption to PEI-cellulose ([@bb1260]). A real-time HTS method measures fluorescence emission resulting from removal of the 3′-terminal dinucleotide, labeled with a quencher, by integrase ([@bb0705]). Han et al. described a fluorescence method to screen molecules that inhibit binding of integrase to viral DNA ([@bb0690]). Methods evaluating the integrase strand transfer reaction have been modified to a high-throughput format using magnetic beads ([@bb0710]) or streptavidin-coated microplates ([@bb0855]). A method to assess strand transfer by time-resolved FRET with a europium-streptavidin-labeled substrate has been optimized for 384- and 1536-well plate formats ([@bb1765]).

3.4. Assay and methods for screening and evaluating viral assembly inhibitors {#s0125}
-----------------------------------------------------------------------------

The HBV capsid protein is the building block of the viral core, surrounding the viral nucleic acid (pre-genomic RNA, pgRNA) and reverse transcriptase. The HBV core is icosahedral, formed by 240 copies of capsid protein dimers. *In vitro* HTS of HBV core assembly inhibitors using a modified HBV capsid protein has been described ([@bb1620]). The capsid protein was modified by deleting the nucleic acid binding domain, which is dispensable for capsid assembly, and the N-terminal assembly domain alone was used in the assay. To fluorescently label the HBV capsid protein, all cysteine residues dispensable for assembly were replaced with alanines. A unique cysteine residue (C150) was C-terminally joined to the assembly domain and labeled with fluorescent BODIPY-FL dye (C150BO). During assembly, capsid proteins dimerize, bringing C150BO residues close together and resulting in C150BO fluorescence self-quenching. Following incubation of the labeled HBV protein with inhibitors, fluorescence was measured in black 96-well microtiter plates.

Development of *in vitro* assembly systems has contributed greatly to current understanding of the structure of retroviral particles and mechanisms of virion formation. These systems also became the base for several high throughput assays for screening assembly inhibitors. During the last 20 years, a number of *in vitro* assembly assays have been established, mainly for HIV-1 ([@bb0230], [@bb0215], [@bb0460], [@bb0635], [@bb0975]), Mason-Pfizer monkey virus ([@bb0160], [@bb0920], [@bb1510], [@bb1505], [@bb1730]), Rous sarcoma virus ([@bb0220], [@bb0225], [@bb1415], [@bb1420]), and murine leukemia virus ([@bb0435], [@bb0660], [@bb0300]). HTS assays for inhibitors of HIV-1 assembly include several methods using purified HIV-1 CA or CA-NC proteins. One of them, the turbidimetric assay, is based on the observation that direct dilution of the HIV-1 capsid protein (CA) into a high-salt solution (1.6--2.2 M NaCl) leads to the formation of tubular structures. As the tube formation is accompanied by an increase in light scattering, assembly can be detected as an increase in turbidity, and the rate of turbidity change is proportional to the rate of the assembly ([@bb0975]). Other method published by Lemke et al., exploits the affinity of nucleocapsid (NC) to a short TG-rich deoxyribooligonucleotide, d(TG25), which is used as a scaffold ([@bb1010]). This arrangement enables CA to assemble at much lower protein and salt concentrations than in the turbidimetric assay ([@bb0975]). Biotin-labeled d(TG25) bound on the surface of neutravidin-coated microtiter well plates nucleates assembly of complexes of CA-NC and soluble fluorescein-labeled d(TG25). Fluorescence is measured after washing to remove the unbound and unassembled material from the captured assembly products ([@bb1010]). Similarly, the FAITH assay uses a dually labeled oligonucleotide (tqON). However, in this case, the ssDNA oligonucleotide tqON is labeled with the reporter dye fluorescein (FAM) as well as Black Hole Quencher (BHQ); thus, it does not emit any fluorescence. The assembly reaction is triggered by mixing HIV-1 CA-NC or a Gag-truncated assembly-competent version with tqON. Following incubation, during which tqON is incorporated into the particles, exonuclease is added to degrade unbound tqON, while co-assembled tqON is protected from cleavage. Degradation of free unbound tqON with *Exo*I results in separation of FAM from its quencher, and the emitted fluorescence is measured ([@bb0665]).

Phage display has been employed to screen peptide inhibitors of HIV-1 assembly ([@bb1610]). A commercial library of M13-derived phages presenting random 12-amino-acid peptides was analyzed for specific binding to purified CA or CA-NC proteins. The specifically bound phages were sequenced, and corresponding peptides were chemically synthesized and re-tested in an *in vitro* assembly assay ([@bb0635]).

Late in the retroviral life cycle, gRNA is incorporated into the nascent particle during assembly at the plasma membrane. NC contains two zinc-finger domains that are responsible for specific binding of gRNA. To screen for compounds that would prevent NC-RNA/DNA interactions, a HTS system consisting of two sequential screens was developed ([@bb0175]). The primary screen uses fluorescence polarization (FP), while the secondary one uses differential scanning fluorimetry (DSF). The combination and order of these two techniques were selected to first identify compounds that disrupt interactions between DNA and NC, and then identify the compounds binding to NC during the secondary screen.

A rapid and simple turbidimetric method was developed to screen inhibitors of assembly of HCV core protein ([@bb0545]). For the *in vitro* assembly reaction, two components, an N-terminal part of the HCV core protein corresponding to the minimal assembly competent domain and RNA corresponding to the full-length 5′UTR of HCV, were used. Assembly of HCV nucleocapsid-like particles was initiated by mixing the purified protein and nucleic acid, and the assembly process was monitored by measuring turbidity at 350 nm.

3.5. Assay and methods for screening and evaluating viral maturation inhibitors {#s0130}
-------------------------------------------------------------------------------

Numerous viruses, including picornaviruses, retroviruses, alphaviruses, and flaviviruses, encode proteases that are essential for their virulence. The majority of viral proteases specifically cleave viral polyprotein precursors to liberate the functional proteins of the virion. Some viral proteases, such as the papain-like proteases of coronaviruses, also reprogram cellular signaling pathways, including ubiquitination mechanisms and interferon controlled responses, to prevent degradation of viral components ([@bb0315], [@bb0540], [@bb1440], [@bb1815]). Numerous viruses, including papillomaviruses ([@bb0185], [@bb0190]) and retroviruses ([@bb0680]), use also host cell proteases, mainly furin, to trim their envelope and surface proteins. This triggers conformational changes required for interaction with cellular receptors and membrane fusion in enveloped viruses. Some viruses use proteases other than furin to modulate their infectivity, as shown for viruses entering airway epithelial cells \[reviewed in ([@bb0980])\] such as influenza virus ([@bb0165], [@bb0950]), Newcastle disease virus ([@bb0600]), and respiratory syncytial virus ([@bb1630]). Extensive research efforts have yielded detailed information about HIV-1 protease and its inhibitors \[reviewed in ([@bb0395], [@bb0935], [@bb1225])\]. Large amounts of data also are available for HCV ([@bb0520], [@bb1355], [@bb1465]) and SARS-CoV 3CL protease inhibitors ([@bb1380]), although there is not yet an inhibitor of the latter target approved for clinical use. Numerous approved drugs are synthetic peptides derived from the natural proteolytic substrates of target viruses modified to improve the *in vivo* effects related to bioavailability, stability, and so on.

Numerous *in vitro* assays to monitor the activity of proteases and their inhibitors, including commercial kits, have been developed. Classical methods use synthetic peptides that mimic the target sites of the protease. Although some of the methods described here were not originally designed to screen the activity of viral proteases in the presence of inhibitors, they can be adapted for this purpose by simply changing the peptide sequence to the target site of the protease of interest. The cleavage yield is usually monitored either colorimetrically ([@bb0430], [@bb1910]) or as a change in fluorescence triggered by the release of fluorescent labels such as 7-amido-4-methylcoumarin (AMC) or rhodamine ([@bb0605]). Fluorogenic substrates have been used to determine the activity of coronavirus proteases and screen inhibitors ([@bb0955], [@bb1000], [@bb1340], [@bb1585], [@bb1700], [@bb1790], [@bb1835], [@bb1885]). Some recently described arrangements employ nanoparticles ([@bb0490], [@bb0905], [@bb1720], [@bb1770], [@bb1860]) or quantum dot bioconjugates ([@bb0995], [@bb1050], [@bb1180]) with immobilized fluorescently or luminescently labeled peptide substrates. Alternatively, cleavage products may be monitored by analysis of proteolytic products by mass spectrometric methods ([@bb0755], [@bb0870], [@bb0985], [@bb1495]), analytical HPLC ([@bb1680]), or electrochemical methods based on the difference in penetration of substrate and cleavage products through the membrane of a polyion-selective sensor ([@bb0570], [@bb0685]). To study the specificity of inhibitor binding and to extend the research to rational design of inhibitors, X-ray or NMR structures of proteases in complex with the inhibitor may be determined, as reported in numerous cases for the proteases of HIV-1 \[reviewed in ([@bb0575])\], HCV ([@bb1840]), and MERS ([@bb1595]).

Cell-based assays can provide additional information, including the capability of the inhibitor to pass through the cell membrane and its stability in the cytoplasm. A general determination of infectivity, such as a plaque cytotoxicity assay in the presence of protease inhibitor, may be used for confirmation. One elegant example exploits the cytotoxicity of HIV protease. Cells are transfected with a protease precursor fused to GFP. In the absence of inhibitor, HIV-1 protease is autocatalytically activated and cleaves a broad variety of cellular proteins, resulting in activation of apoptosis and cell death ([@bb0380], [@bb1500]). This toxic effect, when suppressed by active inhibitors, results in production of a GFP signal in surviving cells ([@bb1075]). Another elegant approach for HIV and coxsackievirus B3 proteases, which both undergo autocatalytic cleavage, employs constructs in which the protease gene is inserted between sequences encoding the DNA-binding domain and the domain that activates transcription of the GAL1-lacZ reporter gene ([@bb0390], [@bb1270]). The protease-mediated cleavage separates the DNA-binding domain from the trans-activating domain and results in failure of reporter gene transcription. This approach has also been modified with GFP as a reporter gene ([@bb0735]). Co-expression of cleavage-activated luciferase substrate and MERS-CoV protease permits both live-cell imaging and quantification of the enzyme activity ([@bb0910]).

4. Conclusion {#s0135}
=============

The need to develop new antiviral compounds will likely persist over the long term, although there has been enormous progress in molecular biology methods, especially RNA silencing, bioinformatics, imaging, and structural biology techniques. Viruses present challenging targets for drug development due their flexibility and adaptability caused by the error-prone copying of their genomes, which can result in emergence of drug-resistant mutants. Viral integration into the host genome and inhibitor toxicity are other obstacles. Here, we provide an overview of *in vitro* methods, including cell-based assays, that may be suitable for screening of antivirotics that interfere with the key steps of viral life cycles and target either virus or cell-encoded proteins required for the infectivity.
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